<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ripretinib: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ripretinib: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ripretinib: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="128325" href="/d/html/128325.html" rel="external">see "Ripretinib: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F54431219"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Qinlock</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F55469022"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Qinlock</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F54402852"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, KIT Inhibitor;</li>
<li>
                        Antineoplastic Agent, PDGFR-alpha Blocker;</li>
<li>
                        Antineoplastic Agent, Tyrosine Kinase Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F54412063"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Withhold ripretinib for at least 1 week prior to elective surgery; do not administer for at least 2 weeks following major surgery and until adequate wound healing has occurred.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="68f8df71-9028-41a5-9040-b8077357fe37">Gastrointestinal stromal tumor, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastrointestinal stromal tumor, advanced:</b>
<b>Oral:</b> 150 mg once daily until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32511981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32511981'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed dose:</i> Administer a missed dose if &lt;8 hours have passed since the missed scheduled dose. If vomiting occurs, do not administer an additional dose; resume at the next scheduled dose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F54412065"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> CrCl calculated by Cockcroft-Gault equation.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≥30 mL/minute: There are no dosage adjustments provided in the manufacturer’s labeling; however, CrCl between 30 to &lt;90 mL/minute did not have any clinically meaningful effect on ripretinib pharmacokinetics.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;30 mL/minute: There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F54412066"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Child-Pugh class A, B, or C: No dosage adjustment necessary.</p></div>
<div class="block dot drugH1Div" id="F54412067"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:0em;display:inline">Recommended dose reduction level for adverse reactions: Reduce ripretinib dose to 100 mg once daily. Permanently discontinue ripretinib if unable to tolerate 100 mg once daily.</p>
<table border="1" frame="border" rules="all">
<caption>
<b>Recommended Ripretinib Dose Reductions for Adverse Reactions</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>Adverse reaction </b></p></th>
<th align="center">
<p style="text-indent:0em;">Severity</p></th>
<th align="center">
<p style="text-indent:0em;">Ripretinib dosage modifications</p></th></tr></thead>
<tbody valign="middle">
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Arthralgia or myalgia</p></td>
<td align="center">
<p style="text-indent:0em;">Grade 2</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold ripretinib until ≤ grade 1 or baseline. If recovered within 7 days, resume ripretinib at same dose; otherwise resume ripretinib at a reduced dose. Consider re-escalating the ripretinib dose if arthralgia or myalgia maintained at ≤ grade 1 or baseline for at least 28 days. If arthralgia or myalgia recur, withhold ripretinib until resolved to ≤ grade 1 or baseline, and then resume ripretinib at a reduced dose (regardless of time to improvement).</p>
<p style="text-indent:0em;">If arthralgia or myalgia recur, withhold ripretinib until resolved to ≤ grade 1 or baseline, and then resume ripretinib at a reduced dose (regardless of time to improvement).</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 3</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold ripretinib for at least 7 days or until ≤ grade 1 or baseline (maximum 28 days), then resume ripretinib at a reduced dose. Consider re-escalating the ripretinib dose if arthralgia or myalgia maintained at ≤ grade 1 or baseline for at least 28 days.</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;">Hypertension</p></td>
<td align="center" colspan="2">
<p style="text-indent:0em;">Initiate or adjust antihypertensive therapy during ripretinib treatment as appropriate.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 3</p></td>
<td align="center">
<p style="text-indent:0em;">If symptomatic, withhold ripretinib until symptoms have resolved and BP is controlled. If BP is controlled to ≤ grade 1 or baseline, resume ripretinib at the same dose; otherwise, resume ripretinib at a reduced dose.</p>
<p style="text-indent:0em;">If grade 3 hypertension recurs, withhold ripretinib until symptoms have resolved and BP is controlled, and then resume ripretinib at a reduced dose.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;">Permanently discontinue ripretinib.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Left ventricular systolic dysfunction</p></td>
<td align="center">
<p style="text-indent:0em;">Grade 3 or 4</p></td>
<td align="center">
<p style="text-indent:0em;">Permanently discontinue ripretinib.</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Palmar-plantar erythrodysesthesia syndrome (PPES)</p></td>
<td align="center">
<p style="text-indent:0em;">Grade 2</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold ripretinib until ≤ grade 1 or baseline. If recovered within 7 days, resume ripretinib at the same dose; otherwise, resume ripretinib at a reduced dose. Consider re-escalating the ripretinib dose if PPES maintained at ≤ grade 1 or baseline for at least 28 days. If PPES recurs, withhold ripretinib until resolved to ≤ grade 1 or baseline, and then resume ripretinib at a reduced dose (regardless of time to improvement).</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 3</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold ripretinib for at least 7 days or until ≤ grade 1 or baseline (maximum 28 days), then resume ripretinib at a reduced dose. Consider re-escalating the ripretinib dose if PPES maintained at ≤ grade 1 or baseline for at least 28 days.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Wound healing complications</p></td>
<td align="center">
<p style="text-indent:0em;">Any</p></td>
<td align="center">
<p style="text-indent:0em;">The safety of resuming ripretinib treatment after resolution of wound healing complications has not been established.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Other adverse reactions</p></td>
<td align="center">
<p style="text-indent:0em;">Grade 3 or 4</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold ripretinib until ≤ grade 1 or baseline (maximum 28 days), and then resume ripretinib at a reduced dose; otherwise permanently discontinue.</p>
<p style="text-indent:0em;">If no recurrence of the adverse reaction for at least 28 days, consider re-escalating the ripretinib dose. If grade 3 or 4 adverse reaction recurs, permanently discontinue ripretinib.</p></td></tr></tbody></table></div>
<div class="block doe drugH1Div" id="F54412064"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F54820681"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Cardiac effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Cardiac effects<b>,</b> including <b>heart failure,</b>
<b>acute coronary syndrome,</b>
<b>acute myocardial infarction</b>, <b>left ventricular failure</b>, <b>reduced ejection fraction,</b>
<b>ventricular hypertrophy,</b> and <b>hypertension</b> have occurred. Only a small portion of cardiac effects led to discontinuation. The safety of ripretinib has not been assessed in patients with a baseline ejection fraction &lt;50%.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Cutaneous malignancy</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Squamous cell carcinoma of the skin</b> (cuSCC), <b>malignant melanoma</b>, and <b>keratoacanthoma </b>have occurred.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed: cuSCC, median time to occurrence was 4.6 months (range: 3.8 to 6 months)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Dermatologic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Dermatologic effects, including <b>palmar-plantar erythrodysesthesia</b> syndrome (PPES), <b>skin photosensitivity</b>, and <b>alopecia</b> have occurred. Only a small portion of these reactions resulted in discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Onset and maximum severity of PPES and alopecia generally occurred simultaneously, suggesting no progressive worsening after first occurrence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-George.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-George.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Photosensitivity:</p>
<p style="text-indent:-2em;margin-left:8em;">• Direct ultraviolet (UV) exposure</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Wound healing impairment</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Wound healing may be adversely affected.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Vascular endothelial growth factor receptor inhibitors are associated with impaired wound healing.</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F54416559"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (14%)<span class="lexi-table-link-container"> (<a aria-label="Hypertension table link" class="lexi-table-link" data-table-id="lexi-content-hypertension" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hypertension')">table 1</a>)</span><span class="table-link" style="display:none;">Hypertension</span>, peripheral edema (17%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hypertension" frame="border" id="lexi-content-hypertension" rules="all">
<caption style="text-align:center;">
<b>Ripretinib: Adverse Reaction: Hypertension</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ripretinib)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ripretinib)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">85</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">43</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (52%)<span class="lexi-table-link-container"> (<a aria-label="Alopecia table link" class="lexi-table-link" data-table-id="lexi-content-alopecia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-alopecia')">table 2</a>)</span><span class="table-link" style="display:none;">Alopecia</span>, palmar-plantar erythrodysesthesia (21%)<span class="lexi-table-link-container"> (<a aria-label="Palmar-Plantar Erythrodysesthesia table link" class="lexi-table-link" data-table-id="lexi-content-palmar-plantar-erythrodysesthesia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-palmar-plantar-erythrodysesthesia')">table 3</a>)</span><span class="table-link" style="display:none;">Palmar-Plantar Erythrodysesthesia</span>, pruritus (11%), xeroderma (13%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Alopecia" frame="border" id="lexi-content-alopecia" rules="all">
<caption style="text-align:center;">
<b>Ripretinib: Adverse Reaction: Alopecia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ripretinib)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ripretinib)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">85</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">43</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Palmar-Plantar Erythrodysesthesia" frame="border" id="lexi-content-palmar-plantar-erythrodysesthesia" rules="all">
<caption style="text-align:center;">
<b>Ripretinib: Adverse Reaction: Palmar-Plantar Erythrodysesthesia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ripretinib)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ripretinib)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">21%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">85</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">43</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum calcium (23%), decreased serum phosphate (26%), decreased serum sodium (17%), increased serum triglycerides (26%), weight loss (19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (36%), constipation (34%), decreased appetite (27%), diarrhea (28%), increased serum amylase (13%), increased serum lipase (32%), nausea (39%), stomatitis (11%), vomiting (21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Increased INR (21%; grades 3/4: 4%), prolonged partial thromboplastin time (35%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (12%), increased serum bilirubin (22%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (42%), headache (19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (18%), increased creatine phosphokinase in blood specimen (21%), muscle spasm (15%), myalgia (32%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (13%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac disorder (2%; including left ventricular failure, ventricular hypertrophy), heart failure (grade 3: 1%)<span class="lexi-table-link-container"> (<a aria-label="Heart Failure table link" class="lexi-table-link" data-table-id="lexi-content-heart-failure" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-heart-failure')">table 4</a>)</span><span class="table-link" style="display:none;">Heart Failure</span> (Blay 2020), ischemic heart disease (1%; including acute coronary syndrome, acute myocardial infarction), reduced ejection fraction (grade 3: 3%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Heart Failure" frame="border" id="lexi-content-heart-failure" rules="all">
<caption style="text-align:center;">
<b>Ripretinib: Adverse Reaction: Heart Failure</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ripretinib)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ripretinib)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Source</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 3: 1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">85</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">43</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Blay 2020</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Malignant melanoma (≤2%), squamous cell carcinoma of skin (5% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (4%), keratoacanthoma (2%), neutropenia (10%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Dermatologic: Skin photosensitivity</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation, hyperesthesia</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthritis</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Wound healing impairment</p></div>
<div class="block coi drugH1Div" id="F54402855"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to ripretinib or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F54412052"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Musculoskeletal toxicity: Arthralgia and/or myalgia have been reported; may require ripretinib treatment interruption and/or dose reduction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Photosensitivity: Patients should limit sun exposure during and for at least 1 week after ripretinib treatment. Advise patients to wear protective clothing and use broad-spectrum UVA/UVB sunscreen.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Surgical patients: Withhold ripretinib for at least 1 week prior to elective surgery; do not administer for at least 2 weeks following major surgery and until adequate wound healing has occurred. The safety of resuming ripretinib treatment after resolution of wound healing complications has not been established.</p></div>
<div class="block foc drugH1Div" id="F54431220"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Qinlock: 50 mg</p></div>
<div class="block geq drugH1Div" id="F54431218"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F54494493"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Qinlock Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $547.80</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F55469023"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Qinlock: 50 mg</p></div>
<div class="block accres drugH1Div" id="F54411474"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Ripretinib is available through a specialty pharmacy network and specialty distributors; information may be found at QinlockHCP.com/resources or at 1.888.724.3274.</p></div>
<div class="block adm drugH1Div" id="F54412196"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer at approximately the same time each day, with or without food. Swallow tablets whole.</p></div>
<div class="block hazard drugH1Div" id="F54692861"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">This medication is not on the NIOSH (2016) list; however, it may meet the criteria for a hazardous drug. Ripretinib may cause teratogenicity and has a structural or toxicity profile similar to existing hazardous agents.</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block use drugH1Div" id="F54402854"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Gastrointestinal stromal tumor, advanced:</b> Treatment of advanced gastrointestinal stromal tumor (GIST) in adults who have previously received treatment with 3 or more kinase inhibitors, including imatinib.</p></div>
<div class="block mst drugH1Div" id="F54411473"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Ripretinib may be confused with avapritinib, ceretinib, imatinib, regorafenib, rucaparib, ruxolitinib, sunitinib.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F54423596"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of BCRP/ABCG2, CYP2C8 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (major), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F54423593"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Androgens: Hypertension-Associated Agents may enhance the hypertensive effect of Androgens. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Ripretinib. Management: Avoid this combination if possible. If concomitant use is required, increase ripretinib to 150 mg twice daily. Decrease ripretinib to 150 mg once daily 14 days after stopping a moderate CYP3A4 inducer. Monitor patients for ripretinib response and toxicity<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Ripretinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase serum concentrations of the active metabolite(s) of Ripretinib. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ripretinib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: May enhance the hypertensive effect of Hypertension-Associated Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F54411477"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to use in patients who could become pregnant.</p>
<p style="text-indent:0em;margin-top:2em;">Patients who could become pregnant should use effective contraception during therapy and for 1 week after the last ripretinib dose. Patients with partners who could become pregnant should use effective contraception during therapy and for 1 week after the last dose of ripretinib.</p></div>
<div class="block pri drugH1Div" id="F54411476"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Based on the mechanism of action and data from animal reproduction studies, in utero exposure to ripretinib may cause fetal harm.</p></div>
<div class="block brc drugH1Div" id="F54411478"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if ripretinib is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during therapy and for at least 1 week after the last ripretinib dose.</p></div>
<div class="block mop drugH1Div" id="F54412198"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Assess ejection fraction by echocardiogram or multigated acquisition (MUGA) scan prior to ripretinib initiation and during treatment as clinically indicated. Monitor BP (prior to and during treatment). Evaluate pregnancy status prior to use in patients who could become pregnant. Perform dermatologic evaluations when initiating ripretinib and routinely during ripretinib treatment. Monitor for signs/symptoms of palmar-plantar erythrodysesthesia syndrome, wound healing impairment, and arthralgia/myalgia. Monitor adherence.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F54412055"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Ripretinib is a switch control tyrosine kinase inhibitor that inhibits KIT proto-oncogene receptor tyrosine kinase (KIT) and platelet derived growth factor receptor A (PDGFRA) kinase signaling (Blay 2020). It binds to both wild type and mutant forms (including primary and secondary mutations) of KIT and PDGRA, preventing the switch from inactive to active conformations of these kinases. Ripretinib also inhibits other kinases, including PDGFRB, TIE2, VEGFR2, and BRAF.</p></div>
<div class="block phk drugH1Div" id="F54412056"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: Ripretinib: 307 L; DP-5439 (active metabolite): 507 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Ripretinib: &gt;99% to albumin and α-1 acid glycoprotein; DP-5439: &gt;99% to albumin and α-1 acid glycoprotein.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Ripretinib: Primarily hepatic via CYP3A4 (major) and CYP2C8 and CYP2D6 (both minor); DP-5439 (active metabolite) via CYP3A4 (major) and CYP2C8, CYP2E1, and CYP2D6 (all minor).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Ripretinib: 14.8 hours; DP-5439: 17.8 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Ripretinib: 4 hours; DP-5439: 15.6 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Ripretinib: Feces (34%); urine (&lt;1%); DP-5439: Feces (6%); Urine: (&lt;1%).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: Ripretinib: 15.3 L/hour; DP-5439: 17.5 L/hour.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F56586843"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Qinlock</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Qinlock</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Qinlock</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Qinlock</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Qinlock</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Qinlock</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Qinlock</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Qinlock</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32511981">
<a name="32511981"></a>Blay JY, Serrano C, Heinrich MC, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncol</i>. 2020;21(7):923-934. doi:10.1016/S1470-2045(20)30168-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ripretinib-drug-information/abstract-text/32511981/pubmed" id="32511981" target="_blank">32511981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-George.2020">
<a name="George.2020"></a>George S, Heinrich MC, Zalcberg JR, et al. Safety profile of ripretinib, including impact of alopecia, and palmar-plantar erythrodysesthesia syndrome (PPES) on patient-reported outcomes (PROs), in ≥ fourth-line advanced gastrointestinal stromal tumors (GIST): analyses from INVICTUS. ASCO Meeting Library. <i>J Clin Oncol</i>. 38: 2020 (suppl; abstr 11539). https://meetinglibrary.asco.org/record/186782/abstract. Accessed May 18, 2020. doi:10.1200/JCO.2020.38.15_suppl.11539</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ripretinib-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Qinlock.1">
<a name="Qinlock.1"></a>Qinlock (ripretinib) [prescribing information]. Waltham, MA: Deciphera Pharmaceuticals LLC; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Qinlock.2">
<a name="Qinlock.2"></a>Qinlock (ripretinib) [product monograph]. Toronto, Ontario, Canada: Medison Pharma Canada Inc; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/</a>. Updated September 2016. Accessed July 24, 2020.</div>
</li></ol></div><div id="topicVersionRevision">Topic 128227 Version 69.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
